JP2024546026A - Ｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストの医薬組成物及びその使用 - Google Patents

Ｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストの医薬組成物及びその使用 Download PDF

Info

Publication number
JP2024546026A
JP2024546026A JP2024527503A JP2024527503A JP2024546026A JP 2024546026 A JP2024546026 A JP 2024546026A JP 2024527503 A JP2024527503 A JP 2024527503A JP 2024527503 A JP2024527503 A JP 2024527503A JP 2024546026 A JP2024546026 A JP 2024546026A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
ala
ile
tyr
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546026A5 (https=
Inventor
振斌 李
菁 陳
雪騰 曹
凱 劉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujian Shengdi Pharmaceutical Co Ltd
Original Assignee
Fujian Shengdi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujian Shengdi Pharmaceutical Co Ltd filed Critical Fujian Shengdi Pharmaceutical Co Ltd
Publication of JP2024546026A publication Critical patent/JP2024546026A/ja
Publication of JP2024546026A5 publication Critical patent/JP2024546026A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2024527503A 2021-11-12 2022-11-11 Ｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストの医薬組成物及びその使用 Pending JP2024546026A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111341752 2021-11-12
CN202111341752.0 2021-11-12
PCT/CN2022/131375 WO2023083301A1 (zh) 2021-11-12 2022-11-11 Glp-1受体和gip受体双重激动剂的药物组合物及其用途

Publications (2)

Publication Number Publication Date
JP2024546026A true JP2024546026A (ja) 2024-12-17
JP2024546026A5 JP2024546026A5 (https=) 2025-11-11

Family

ID=86335124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527503A Pending JP2024546026A (ja) 2021-11-12 2022-11-11 Ｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストの医薬組成物及びその使用

Country Status (10)

Country Link
US (1) US20250115654A1 (https=)
EP (1) EP4431522A4 (https=)
JP (1) JP2024546026A (https=)
KR (1) KR20240109258A (https=)
CN (1) CN118103391A (https=)
AU (1) AU2022386489A1 (https=)
CA (1) CA3237796A1 (https=)
MX (1) MX2024005663A (https=)
TW (1) TW202333773A (https=)
WO (1) WO2023083301A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116693652B (zh) * 2023-08-02 2024-01-05 北京惠之衡生物科技有限公司 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用
TW202529797A (zh) * 2023-12-12 2025-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途
WO2025149039A1 (zh) * 2024-01-12 2025-07-17 杭州中美华东制药有限公司 长效glp-1/gip双激动剂的药物组合物
WO2025252197A1 (zh) * 2024-06-07 2025-12-11 江苏恒瑞医药股份有限公司 药物组合物
WO2026037397A1 (zh) * 2024-08-16 2026-02-19 江苏恒瑞医药股份有限公司 Glp-1类似物的医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101987868B (zh) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
WO2012088379A2 (en) * 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
US9453062B2 (en) * 2011-06-10 2016-09-27 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
IN2014MN02304A (https=) * 2012-05-03 2015-08-07 Zealand Pharma As
AU2013366692B2 (en) * 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
EP3642238A1 (en) * 2017-06-21 2020-04-29 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
SG11202103137WA (en) * 2018-10-26 2021-04-29 Novo Nordisk As Stable semaglutide compositions and uses thereof
CN112351994B (zh) * 2019-04-11 2024-06-07 江苏豪森药业集团有限公司 一种多受体激动剂及其医药用途
US20220372072A1 (en) * 2019-09-19 2022-11-24 Dr. Reddy's Laboratories Limited Improved purification processes for liraglutide
EP4086277A4 (en) * 2019-12-30 2024-02-14 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting glp-1 compound
CN114222755B (zh) * 2020-05-29 2024-06-11 北京拓界生物医药科技有限公司 Glp-1和gip受体双重激动剂化合物及其应用

Also Published As

Publication number Publication date
MX2024005663A (es) 2024-05-28
EP4431522A1 (en) 2024-09-18
EP4431522A4 (en) 2025-03-26
KR20240109258A (ko) 2024-07-10
AU2022386489A1 (en) 2024-05-23
CA3237796A1 (en) 2023-05-19
US20250115654A1 (en) 2025-04-10
TW202333773A (zh) 2023-09-01
WO2023083301A1 (zh) 2023-05-19
CN118103391A (zh) 2024-05-28

Similar Documents

Publication Publication Date Title
TWI910174B (zh) Ｇｌｐ-１和ｇｉｐ受體雙重激動劑化合物及其應用
US8501693B2 (en) Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
JP2024546026A (ja) Ｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストの医薬組成物及びその使用
US20220168396A1 (en) Multi-receptor agonist and medical use thereof
US20090209469A1 (en) Use of Exendins and GLP-1 Receptor Agonists for Altering Lipoprotein Particle Size and Subclass Composition
CN113383014B (zh) 双受体重激动剂化合物及其药物组合物
JP2011506442A (ja) インスリン分泌性ペプチド結合体の製剤
US20260014232A1 (en) Pharmaceutical Composition of GLP-1 and GIP Receptor Dual Agonist and Use Thereof
TW202502808A (zh) Glp-1、gip和gcg受體三激動劑及其應用
RU2848325C1 (ru) Соединение с двойной агонистической активностью в отношении рецепторов glp-1 и gip и его применение
EA053272B1 (ru) Фармацевтическая композиция двойного агониста рецептора glp-1 и рецептора gip и ее применение
WO2025252197A1 (zh) 药物组合物
HK40069563B (zh) Glp-1和gip受体双重激动剂化合物及其应用
HK40069563A (en) Dual-agonist compound for both glp-1 and gip receptors and application thereof
HK40051504A (en) Dual receptor-acting agonist compounds and pharmaceutical composition thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251031

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260116